Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial

Recruiting now · Phase 2

Conditions studied: Cervical Cancer, Immunochemotherapy

In brief

Efficacy evaluation of camrelizumab combined with chemotherapy for adjuvant treatment of patients with pathologically confirmed lymph node-positive cervical cancer after staging surgery.

Key facts

Study ID

NCT07167160

Run by

Women's Hospital School Of Medicine Zhejiang University

People needed

59

Starts

2025-03-10

Expected to finish

2029-12-31

Last updated by the study team

2025-12-18

Who can join

Age: 18 and older, up to 70. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Patients with cervical cancer staged FIGO2018 IIIC1p or IIIC2p after radical surgery;
• Positive PD-L1 expression;
• ECOG score ≤1

You may not qualify if…

• Positive parametrium or surgical margin;
• Incomplete radical surgery;
• Residual target lesions;
• Active autoimmune disease or autoimmune disease requiring systemic treatment;
• Previous treatment with immune checkpoint inhibitors.

Where it is running

• Women's Hospital, School of Medicine, Zhejiang University — Hangzhou, Zhejiang, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.